Status:

COMPLETED

A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma

Lead Sponsor:

National Health Research Institutes, Taiwan

Collaborating Sponsors:

China Medical University Hospital

National Cheng-Kung University Hospital

Conditions:

Oral Cancer

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC (LAOSCC). Although the treatment could provide prompt local control, but it ...

Detailed Description

Patients with high-risk, locally advanced (TxN2b\~3 or T4N0\~3, M0) OSCC will be eligible. To detect an interested objective response rate (p1) of 80% versus a non-interested response (p0) rate of 60%...

Eligibility Criteria

Inclusion

  • High-risk, locally advanced (TxN2b\~3 or unresectable T4, M0) OSCC
  • Histologically confirmed squamous cell carcinoma
  • Performance status: Eastern Cooperative Oncology Group performance status (ECOG) 0-1
  • age 18 years or older, less than 70 years of age
  • Having signed informed consent
  • Measurable disease by CT or MRI
  • Adequate hematologic, hepatic and renal function

Exclusion

  • Prior radiotherapy for targeted lesions, chemotherapy, EGFR pathway targeting therapy
  • Prior surgery for cancer except for the purpose of diagnostic biopsy
  • Concomitant active 2nd malignancies or disease-free of malignancies \< 3 years before the study except adequately treated in situ cervical cancer, or non-melanoma skin cancer
  • Concomitant anticancer therapies within the past 28 days
  • Severe cardiopulmonary diseases and other systemic disease under poor control
  • Uncontrolled chronic neuropathy
  • Women who are positive of pregnancy, or in breast-feeding
  • Known allergy to any study treatment
  • Legal incapacity
  • Significant disease which, in the investigator's opinion, would exclude the patient from the study

Key Trial Info

Start Date :

September 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2013

Estimated Enrollment :

47 Patients enrolled

Trial Details

Trial ID

NCT00933387

Start Date

September 1 2009

End Date

November 1 2013

Last Update

May 4 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Health Research of Institutes, Taiwan Cooperative Oncology Group

Tainan, Taiwan